Have a feature idea you'd love to see implemented?
Let us know!
TNGX Tango Therapeutics Inc
Price (delayed)
$3.92
Market cap
$421.08M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.16
Enterprise value
$405.56M
tango therapeutics is a biotechnology company discovering and developing novel medicines targeting cancer vulnerabilities to deliver transformational new therapies for patients. tango was launched in 2017 with a $55 million
Highlights
The gross profit rose by 16% year-on-year and by 2.1% since the previous quarter
The revenue rose by 16% YoY and by 2.1% QoQ
Tango Therapeutics's quick ratio has increased by 6% from the previous quarter but it has decreased by 6% YoY
The company's net income fell by 23% YoY and by 6% QoQ
The equity has decreased by 17% YoY and by 7% QoQ
Key stats
What are the main financial stats of TNGX
Market
Valuations
Earnings
Shares outstanding
107.42M
Market cap
$421.08M
Enterprise value
$405.56M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.83
Price to sales (P/S)
9.8
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
9.35
Revenue
$43.38M
EBIT
-$123.19M
EBITDA
-$116.99M
Free cash flow
-$123.18M
Per share
Balance sheet
Liquidity
EPS
-$1.16
Free cash flow per share
-$1.14
Book value per share
$2.14
Revenue per share
$0.4
TBVPS
$3.25
Total assets
$352.42M
Total liabilities
$123.25M
Debt
$37.63M
Equity
$229.17M
Working capital
$263.23M
Debt to equity
0.16
Current ratio
8
Quick ratio
7.8
Net debt/EBITDA
0.13
Margins
Efficiency
Dividend
EBITDA margin
-269.7%
Gross margin
100%
Net margin
-284.4%
Operating margin
-322%
Return on assets
-32%
Return on equity
-49.6%
Return on invested capital
-38.1%
Return on capital employed
-39.1%
Return on sales
-284%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
TNGX stock price
How has the Tango Therapeutics stock price performed over time
Intraday
7.99%
1 week
1.82%
1 month
-40.96%
1 year
-49.61%
YTD
-60.4%
QTD
-49.09%
Financial performance
How have Tango Therapeutics's revenue and profit performed over time
Revenue
$43.38M
Gross profit
$43.38M
Operating income
-$139.7M
Net income
-$123.4M
Gross margin
100%
Net margin
-284.4%
Tango Therapeutics's operating income has decreased by 27% YoY and by 5% QoQ
The company's net income fell by 23% YoY and by 6% QoQ
The gross profit rose by 16% year-on-year and by 2.1% since the previous quarter
The revenue rose by 16% YoY and by 2.1% QoQ
Growth
What is Tango Therapeutics's growth rate over time
Valuation
What is Tango Therapeutics stock price valuation
P/E
N/A
P/B
1.83
P/S
9.8
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
9.35
Tango Therapeutics's EPS has decreased by 4.5% YoY and by 3.6% QoQ
The stock's P/B is 49% less than its last 4 quarters average of 3.6
The equity has decreased by 17% YoY and by 7% QoQ
TNGX's price to sales (P/S) is 58% lower than its 5-year quarterly average of 23.6 and 56% lower than its last 4 quarters average of 22.5
The revenue rose by 16% YoY and by 2.1% QoQ
Efficiency
How efficient is Tango Therapeutics business performance
The ROA is down by 32% year-on-year and by 11% since the previous quarter
TNGX's ROIC is down by 30% YoY and by 11% from the previous quarter
The ROE is down by 20% year-on-year and by 11% since the previous quarter
Tango Therapeutics's return on sales has decreased by 7% YoY and by 3.8% QoQ
Dividends
What is TNGX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for TNGX.
Financial health
How did Tango Therapeutics financials performed over time
The total assets is 186% more than the total liabilities
The total liabilities is down by 19% year-on-year and by 8% since the previous quarter
The total assets has contracted by 18% YoY and by 8% from the previous quarter
The debt is 84% less than the equity
The equity has decreased by 17% YoY and by 7% QoQ
The debt to equity has grown by 14% year-on-year and by 7% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.